It has also been shown that CTC detection in postoperative patients with stage ΙΙ CRC is an independent prognostic marker that detects disease recurrence 4 months earlier than clinically established carcinoembryonic antigen (CEA) [22]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.